No, GILD valuation in GS report included total addressable market, see page 3, revenue estimates for GILD HCV are $61B 2014-2019, $131B 2014-2027. The point of total addressable market, both diagnosed and undercare, was to show GILD estimates relative to total addressable market 2014-2019: 26% of diagnosed, 94% undercare; 2014-2027: 55% of diagnosed, 200% of undercare. Thus the point of high expectation and the need to capture/expand patient pool to achieve revenue estimates.
Market Data 
Markets 
AI
